News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Hamilton James C
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 07/05/2023 |
4
| Hamilton James C (Chief Discovery/Trans Medicine) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Sold 3,000 shares
@ $35.53, valued at
$106.6k
|
|
| 01/06/2023 |
4
| Hamilton James C (Chief Discovery/Trans Medicine) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Sold 7,230 shares
@ $37.4, valued at
$270.4k
Sold 6,573 shares
@ $37.4, valued at
$245.8k
|
|
| 01/05/2023 |
4
| Hamilton James C (Chief Discovery/Trans Medicine) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Sold 1,194 shares
@ $37.46, valued at
$44.7k
Sold 2,837 shares
@ $38.53, valued at
$109.3k
Sold 300 shares
@ $39.74, valued at
$11.9k
Sold 136 shares
@ $40.54, valued at
$5.5k
Sold 1,642 shares
@ $37.49, valued at
$61.6k
Sold 3,682 shares
@ $38.52, valued at
$141.8k
Sold 300 shares
@ $39.56, valued at
$11.9k
Sold 247 shares
@ $40.52, valued at
$10k
Granted 60,000 shares
@ $0 |
|
| 01/06/2022 |
4
| Hamilton James C (Senior Vice President) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Sold 9,955 shares
@ $64.89, valued at
$646k
Sold 7,469 shares
@ $65.59, valued at
$489.9k
Sold 802 shares
@ $67.39, valued at
$54k
Sold 649 shares
@ $68.12, valued at
$44.2k
Sold 500 shares
@ $69.38, valued at
$34.7k
Sold 2,290 shares
@ $60.51, valued at
$138.6k
Sold 2,100 shares
@ $61.84, valued at
$129.9k
Sold 1,100 shares
@ $62.64, valued at
$68.9k
Sold 700 shares
@ $63.68, valued at
$44.6k
Sold 60 shares
@ $64.35, valued at
$3.9k
|
|
| 01/04/2022 |
4
| Hamilton James C (Senior Vice President) has filed a Form 4 on ARROWHEAD PHARMACEUTICALS, INC.|
Txns:
| Granted 55,000 shares
@ $0 |
|
| 01/15/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/07/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/05/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|
|